For the first time, the FDA approves a CBD-containing drug

As I have written in previous posts, CBD, or cannabidiol, an active ingredient of marijuana, kills myeloma cells, so the news I came across early this morning is of huge interest to me.

In a nutshell, for the first time ever, the FDA has approved a CBD-containing oral solution (= a strawberry-flavored syrup) for the treatment of rare but severe forms of epilepsy in children.

Note: this syrup does not contain THC, the ingredient in marijuana that makes people “high.”

It may not come without side effects, such as sleepiness and increased liver enzymes (like most anti-seizure drugs, it appears), as you can read in the FDA press release:

Compared to seizures, however, the potential side effects seem tolerable. Here’s a Time magazine story about a 10-year-old girl with Dravet syndrome who participated in the CBD clinical trial in 2016, for example:

Anyway, I think this is very exciting…and promising…!!!


  1. Ciao, with curcumin 8gr, now I am on CBD oil 4% (produced here in Italy) the commerce of CBD oil was recently approved, you can buy it in ‘erboristeria. I started a month ago, my follow up is at the end of August, I will let you know.

  2. I just found a small roll on form of CBD oil in a n organic food store and used it on my neck to release a muscle spasm and it worked.

  3. I am just reading a fascinating book “Why We Sleep” by Matthew Walker, a sleep scientist. The section on cancer and our immune system affected by lack of sleep is a must read.

  4. Crystal structure reveals how curcumin impairs cancer

    “”The enzyme kinases IKK and GSK3 were thought to be the prime curcumin-targets that lead to anti-cancer effect but the co-crystal structure of curcumin with DYRK2 along with a 140-panel kinase inhibitor profiling reveal that curcumin binds strongly to the active site of DYRK2, inhibiting it at a level that is 500 times more potent than IKK or GSK3.”

    Working alongside Jack E. Dixon, PhD, Distinguished Professor of Pharmacology, Cellular and Molecular Medicine, Chemistry and Biochemistry at UC San Diego, Banerjee and team have been looking for regulators of proteasomes to inhibit tumor formation by proteasome-addicted cancers like triple-negative breast cancer (TNBC) and the plasma cell malignancy called multiple myeloma.

    Using biochemical, mouse cancer models and cellular models the team found that curcumin is a selective inhibitor of DYRK2 and that this novel molecular target has promising anticancer potential for not only chemo-sensitive but also proteasome inhibitor resistant/adapted cancers.”

Leave a Reply

Your email address will not be published. Required fields are marked *